IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.…
Idl Diagnostics — Analyserat bolag
IDL Diagnostics (STO: IDLDX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 25 employees.
The shares were at 0.3030 SEK on 20 November 2026, down 31.8% over 52 weeks. Its 52-week range is 0.2500 SEK to 0.5300 SEK: the price is 42.8% below the high and 21.2% above the low.
Its market capitalisation is 69.80M SEK.
IDL Diagnostics reports return on equity of -8.2%, an operating margin of -5.1% and revenue down 2.8% year over year.
It holds more cash than debt, a net cash position of 21.57M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.